DK3661954T3 - Interleukin-21-muteiner og fremgangsmåder til behandling - Google Patents
Interleukin-21-muteiner og fremgangsmåder til behandling Download PDFInfo
- Publication number
- DK3661954T3 DK3661954T3 DK18759207.6T DK18759207T DK3661954T3 DK 3661954 T3 DK3661954 T3 DK 3661954T3 DK 18759207 T DK18759207 T DK 18759207T DK 3661954 T3 DK3661954 T3 DK 3661954T3
- Authority
- DK
- Denmark
- Prior art keywords
- muteins
- interleukin
- treatment
- methods
- Prior art date
Links
- 102100030704 Interleukin-21 Human genes 0.000 title 1
- 108010074108 interleukin-21 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540692P | 2017-08-03 | 2017-08-03 | |
| US201862616733P | 2018-01-12 | 2018-01-12 | |
| PCT/US2018/045105 WO2019028316A1 (en) | 2017-08-03 | 2018-08-03 | INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3661954T3 true DK3661954T3 (da) | 2022-04-19 |
Family
ID=63350603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18759207.6T DK3661954T3 (da) | 2017-08-03 | 2018-08-03 | Interleukin-21-muteiner og fremgangsmåder til behandling |
Country Status (37)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3072099A1 (en) | 2017-08-11 | 2019-02-14 | Research Development Foundation | Engineered antibody fc variants for enhanced serum half life |
| WO2019207942A1 (ja) * | 2018-04-27 | 2019-10-31 | OTA Takayo | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー |
| US12459980B2 (en) * | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| US20230071889A1 (en) * | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| JP2022520998A (ja) * | 2019-02-22 | 2022-04-04 | アンウィタ バイオサイエンシス， インク． | アルブミン結合抗体及びその使用 |
| WO2020223392A2 (en) * | 2019-04-30 | 2020-11-05 | Totient, Inc. | Cancer associated antibody compositions and methods of use |
| EP4055060B1 (en) * | 2019-11-08 | 2025-07-09 | Amgen Inc. | Engineering charge pair mutations for pairing of hetero-igg molecules |
| WO2021092719A1 (zh) * | 2019-11-11 | 2021-05-20 | 王盛典 | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 |
| US11692020B2 (en) | 2019-11-20 | 2023-07-04 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
| CN111087473B (zh) * | 2019-12-11 | 2022-06-14 | 上海百英生物科技有限公司 | 一种SIRPa-Fc-IL21融合蛋白及其应用 |
| MX2022014974A (es) | 2020-05-26 | 2023-01-11 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1. |
| EP4174088A4 (en) * | 2020-06-30 | 2024-01-24 | GI Innovation, Inc. | FUSION PROTEIN WITH ANTI-LAG-3 ANTIBODIES AND IL-2 AND USE THEREOF |
| CN111925990B (zh) * | 2020-09-02 | 2022-08-26 | 北京立康生命科技有限公司 | 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法 |
| MX2023004598A (es) | 2020-10-23 | 2023-06-29 | Asher Biotherapeutics Inc | Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias. |
| AU2021370625A1 (en) * | 2020-10-26 | 2023-06-01 | Oren BESKE | Orthogonal il-21 receptor/cytokine systems |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| CN116829194A (zh) * | 2020-12-09 | 2023-09-29 | 亚设生物治疗公司 | 用于工程化细胞疗法的靶向细胞因子构建体 |
| EP4273158A1 (en) * | 2020-12-23 | 2023-11-08 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-21 mutant and use thereof |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| JP2024515263A (ja) * | 2021-04-09 | 2024-04-08 | オーエスイー・イミュノセラピューティクス | 改善された特性を有する二機能性分子のための新規足場構造 |
| AU2022263986A1 (en) | 2021-04-27 | 2023-11-09 | Amgen Inc. | Modulating product quality of asymmetric multispecific antibodies through the use of temperature |
| GB2638094A (en) * | 2021-05-19 | 2025-08-13 | Asher Biotherapeutics Inc | Il-21 Polypeptides And Targeted Constructs |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| CA3227990A1 (en) * | 2021-08-06 | 2023-02-09 | Amgen Inc. | Isolation of therapeutic protein |
| AU2022350320A1 (en) * | 2021-09-24 | 2024-04-11 | Bionsystems Inc | Fusion protein dimer including pd-1 and il-21, and use thereof |
| KR20240067113A (ko) * | 2021-09-30 | 2024-05-16 | 유노비아 주식회사 | Il-21r 뮤테인을 포함하는 면역 사이토카인 |
| WO2023205738A2 (en) * | 2022-04-20 | 2023-10-26 | Neptune Biosciences Llc | Orthogonal il-21 receptor/cytokine systems |
| CA3255321A1 (en) * | 2022-05-05 | 2023-11-09 | Amgen Research (Munich) Gmbh | HETEROMULTIMER BINDING TO DLL3 AND CD3 |
| KR102796245B1 (ko) * | 2022-05-10 | 2025-04-18 | 아주대학교산학협력단 | 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
| EP4547702A1 (en) * | 2022-06-29 | 2025-05-07 | Beijing Neox Biotech Limited | Il-21 polypeptides and methods of use |
| CN117645669B (zh) * | 2022-08-29 | 2024-11-01 | 星奕昂(上海)生物科技有限公司 | 具有膜结合型il-21的免疫细胞及其制法和应用 |
| CN117645661A (zh) * | 2022-09-02 | 2024-03-05 | 北京志道生物科技有限公司 | 一种聚乙二醇修饰的il-21衍生物及其应用 |
| WO2024228173A2 (en) * | 2023-05-04 | 2024-11-07 | Peptone, Ltd. | Engineered cytokines and uses thereof |
| WO2025191144A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of egfr-specific antigen binding proteins and cytokines |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191133A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| EP4644413A1 (en) * | 2024-05-03 | 2025-11-05 | Genmab B.V. | Binding agents having altered fc-mediated effector functions |
| WO2025251226A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell |
| CN118546233B (zh) * | 2024-07-30 | 2024-10-18 | 成都微芯新域生物技术有限公司 | 白介素-21突变体及其应用 |
| CN119954928B (zh) * | 2025-02-12 | 2025-12-02 | 华润生物医药有限公司 | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 |
| CN119978098A (zh) * | 2025-02-12 | 2025-05-13 | 华润生物医药有限公司 | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 |
| CN119954929B (zh) * | 2025-02-12 | 2025-12-02 | 华润生物医药有限公司 | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 |
Family Cites Families (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5855885A (en) | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| EP1053752A1 (en) | 1998-02-10 | 2000-11-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| WO2000040734A1 (en) | 1998-12-31 | 2000-07-13 | Arch Development Corporation | Recombinant herpes simplex virus useful for treating neoplastic disease |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| ES2254359T3 (es) | 2000-01-21 | 2006-06-16 | Biovex Limited | Cepa viral para el tratamiento oncolitico de canceres. |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EP1381280B1 (en) | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Viral vectors and their use in therapeutic methods |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| DK1451322T3 (da) | 2001-11-05 | 2010-02-01 | Zymogenetics Inc | Il-21-antagonister |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US7494804B2 (en) | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| US7736652B2 (en) | 2002-03-21 | 2010-06-15 | The Regents Of The University Of California | Antibody fusion proteins: effective adjuvants of protein vaccination |
| PT1531850E (pt) | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| DE60331455D1 (de) | 2002-10-04 | 2010-04-08 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
| CN1513993A (zh) | 2002-12-31 | 2004-07-21 | 北京博泰迪生物工程科技开发有限公司 | 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列 |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| WO2005030196A2 (en) | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| KR20120125634A (ko) | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| BRPI0511782B8 (pt) | 2004-06-03 | 2021-05-25 | Novimmune Sa | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| EP1861399B1 (en) | 2005-03-14 | 2011-12-14 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
| WO2006111524A2 (en) | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| PL1963369T3 (pl) | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| US7592427B2 (en) | 2005-11-28 | 2009-09-22 | Zymogenetics, Inc. | Antibodies to IL-21 receptor |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| BRPI0709787A2 (pt) | 2006-05-08 | 2011-03-29 | Philogen Spa | citocinas com anticorpos alvejados para terapia |
| CN101553501A (zh) | 2006-10-26 | 2009-10-07 | 诺沃-诺迪斯克有限公司 | Il-21变种 |
| CA2671665A1 (en) | 2006-12-21 | 2008-06-26 | Novo-Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| SG182234A1 (en) | 2007-04-03 | 2012-07-30 | Amgen Res Munich Gmbh | Cross-species-specific cd3-epsilonbinding domain |
| PT2520590T (pt) | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| RU2422134C1 (ru) | 2007-04-19 | 2011-06-27 | Донг-А Фармасьютикал. Ко., Лтд | Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав |
| EP2426146B1 (en) | 2007-12-07 | 2016-02-17 | ZymoGenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102089325A (zh) | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| AU2009299792B2 (en) | 2008-10-01 | 2015-07-16 | Amgen Research (Munich) Gmbh | Cross-species-specific PSMAxCD3 bispecific single chain antibody |
| US20120107267A1 (en) * | 2009-03-11 | 2012-05-03 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
| CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| KR20120053042A (ko) | 2009-08-17 | 2012-05-24 | 로슈 글리카트 아게 | 표적화된 면역접합체 |
| CN102741280B (zh) | 2009-10-30 | 2015-12-02 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
| EP2686682A4 (en) | 2011-03-11 | 2015-03-11 | Amgen Inc | METHOD FOR CORRELATED MUTATION ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CN104011072B (zh) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US20130028882A1 (en) | 2011-07-07 | 2013-01-31 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
| PL2753355T3 (pl) | 2011-09-08 | 2019-04-30 | Benevir Biopharm Inc | Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze |
| ES3033729T3 (en) | 2011-10-28 | 2025-08-07 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| US20150030562A1 (en) | 2011-12-23 | 2015-01-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of treating or preventing viral diseases by blocking interleukin-21 |
| US9447160B2 (en) | 2012-01-19 | 2016-09-20 | University Of Miami | Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| CA3004695C (en) | 2012-04-30 | 2020-08-04 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| AR092044A1 (es) | 2012-08-07 | 2015-03-18 | Roche Glycart Ag | Inmunoterapia mejorada |
| US20140128326A1 (en) | 2012-11-08 | 2014-05-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014139468A1 (en) | 2013-03-15 | 2014-09-18 | Admark Healthcare, Llc | Fusion protein molecules and method of use |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| WO2015000585A1 (en) * | 2013-07-02 | 2015-01-08 | Walter Sebald | Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group |
| KR102361237B1 (ko) | 2013-07-11 | 2022-02-09 | 더 스크립스 리서치 인스티튜트 | 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물 |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CA2935665A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| AU2015221181B2 (en) | 2014-02-19 | 2020-08-20 | Merck Patent Gmbh | Cancer-targeted IL-12 immunotherapy |
| LT3128997T (lt) | 2014-04-08 | 2020-10-12 | Boston Pharmaceuticals Inc. | Surišančios molekulės, specifinės il-21, ir jų panaudojimas |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| WO2016100375A2 (en) | 2014-12-15 | 2016-06-23 | Washington University | Compositions and methods for targeted cytokine delivery |
| WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
| CN107249633A (zh) | 2014-12-19 | 2017-10-13 | 迈博太科公司 | 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法 |
| KR20160113452A (ko) | 2015-03-20 | 2016-09-29 | (주)엘지하우시스 | 진공 단열재용 심재 및 진공단열재 |
| ES2898958T3 (es) | 2015-07-30 | 2022-03-09 | Macrogenics Inc | Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3328377A4 (en) | 2015-07-31 | 2019-03-13 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES |
| US11008391B2 (en) | 2015-08-11 | 2021-05-18 | WuXi Biologics Ireland Limited | Anti-PD-1 antibodies |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| UA123826C2 (uk) | 2015-10-02 | 2021-06-09 | Ф. Хоффманн-Ля Рош Аг | Антитіла до pd1 та способи їх застосування |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| PT3394103T (pt) * | 2015-12-22 | 2023-09-04 | Regeneron Pharma | Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro |
| CN109415703B (zh) | 2016-01-08 | 2024-08-30 | 雷普利穆内有限公司 | 经修饰的溶瘤病毒 |
| WO2017123643A1 (en) | 2016-01-11 | 2017-07-20 | Flagship Pioneering, Inc. | Methods and compositions for modulating thymic function |
| SG11201805770UA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs |
| UY37105A (es) | 2016-02-03 | 2017-09-29 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| CA3013554A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Targeted therapeutic agents and uses thereof |
| US11053293B2 (en) | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| US11186641B2 (en) | 2016-03-17 | 2021-11-30 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US20190183931A1 (en) | 2016-04-01 | 2019-06-20 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| US12162919B2 (en) | 2016-08-01 | 2024-12-10 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| EA201990672A1 (ru) | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты |
| DK3515938T3 (da) | 2016-09-21 | 2025-04-07 | Cstone Pharmaceuticals | Monoklonale antistoffer mod programmeret død 1 (pd-1) |
| WO2018057943A1 (en) | 2016-09-23 | 2018-03-29 | Oncosec Medical Incorporated | Modulating responses to checkpoint inhibitor therapy |
| SI3535298T1 (sl) | 2016-11-02 | 2022-01-31 | Jounce Therapeutics, Inc. | Protitelesa proti pd-1 in njihove uporabe |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN107082812B (zh) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| AU2018298060B2 (en) | 2017-07-03 | 2021-02-25 | Torque Therapeutics, Inc. | Immunostimulatory fusion molecules and uses thereof |
| US20210260163A1 (en) | 2018-03-09 | 2021-08-26 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| CA3095310A1 (en) | 2018-03-28 | 2019-10-03 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
| KR20210018797A (ko) | 2018-04-10 | 2021-02-18 | 암젠 인크 | Dll3에 대한 키메라 수용체 및 이의 사용 방법 |
| KR20210021486A (ko) | 2018-06-18 | 2021-02-26 | 안위타 바이오사이언시스, 인코포레이티드 | 사이토카인 융합 단백질 및 이의 용도 |
| CN113164558A (zh) | 2018-09-28 | 2021-07-23 | 皮埃尔法布雷医药公司 | 用于治疗癌症的新型免疫细胞因子 |
| WO2020127369A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
-
2018
- 2018-08-03 CR CR20200099A patent/CR20200099A/es unknown
- 2018-08-03 PE PE2024003085A patent/PE20250757A1/es unknown
- 2018-08-03 MX MX2020001328A patent/MX2020001328A/es unknown
- 2018-08-03 TW TW107127071A patent/TWI798245B/zh active
- 2018-08-03 JO JOP/2020/0020A patent/JOP20200020B1/ar active
- 2018-08-03 EP EP21217086.4A patent/EP4029877B1/en active Active
- 2018-08-03 IL IL272137A patent/IL272137B2/en unknown
- 2018-08-03 DK DK18759207.6T patent/DK3661954T3/da active
- 2018-08-03 KR KR1020207005850A patent/KR102414120B1/ko active Active
- 2018-08-03 SG SG11202000821SA patent/SG11202000821SA/en unknown
- 2018-08-03 AU AU2018311079A patent/AU2018311079B2/en active Active
- 2018-08-03 US US16/054,035 patent/US11541103B2/en active Active
- 2018-08-03 PL PL18759207T patent/PL3661954T3/pl unknown
- 2018-08-03 ES ES21217086T patent/ES2975221T3/es active Active
- 2018-08-03 LT LTEPPCT/US2018/045105T patent/LT3661954T/lt unknown
- 2018-08-03 RS RS20220350A patent/RS63101B1/sr unknown
- 2018-08-03 EP EP18759207.6A patent/EP3661954B1/en active Active
- 2018-08-03 PE PE2020000167A patent/PE20200867A1/es unknown
- 2018-08-03 MY MYPI2020000420A patent/MY195974A/en unknown
- 2018-08-03 CN CN201880064079.0A patent/CN111164100B/zh active Active
- 2018-08-03 WO PCT/US2018/045105 patent/WO2019028316A1/en not_active Ceased
- 2018-08-03 SM SM20220162T patent/SMT202200162T1/it unknown
- 2018-08-03 TN TNP/2020/000015A patent/TN2020000015A1/en unknown
- 2018-08-03 ES ES18759207T patent/ES2910969T3/es active Active
- 2018-08-03 TW TW111130464A patent/TWI844073B/zh active
- 2018-08-03 HU HUE18759207A patent/HUE058233T2/hu unknown
- 2018-08-03 HR HRP20220404TT patent/HRP20220404T1/hr unknown
- 2018-08-03 SI SI201830619T patent/SI3661954T1/sl unknown
- 2018-08-03 UA UAA202001391A patent/UA130113C2/uk unknown
- 2018-08-03 JP JP2018146505A patent/JP7079171B2/ja active Active
- 2018-08-03 MA MA56289A patent/MA56289B1/fr unknown
- 2018-08-03 CN CN202410297683.5A patent/CN118126157A/zh active Pending
- 2018-08-03 KR KR1020227021497A patent/KR20220092652A/ko active Pending
- 2018-08-03 BR BR122021015266-7A patent/BR122021015266B1/pt active IP Right Grant
- 2018-08-03 PT PT187592076T patent/PT3661954T/pt unknown
- 2018-08-03 BR BR112020002013-3A patent/BR112020002013B1/pt active IP Right Grant
- 2018-08-03 CA CA3071376A patent/CA3071376A1/en active Pending
- 2018-08-03 UY UY0001037829A patent/UY37829A/es active IP Right Grant
-
2020
- 2020-01-29 CL CL2020000252A patent/CL2020000252A1/es unknown
- 2020-01-30 CO CONC2020/0001113A patent/CO2020001113A2/es unknown
- 2020-01-30 PH PH12020500231A patent/PH12020500231A1/en unknown
- 2020-01-31 MX MX2023013462A patent/MX2023013462A/es unknown
- 2020-02-03 SA SA520411230A patent/SA520411230B1/ar unknown
- 2020-02-03 SA SA522432917A patent/SA522432917B1/ar unknown
- 2020-02-27 ZA ZA2020/01251A patent/ZA202001251B/en unknown
-
2022
- 2022-02-04 CL CL2022000300A patent/CL2022000300A1/es unknown
- 2022-04-12 CY CY20221100274T patent/CY1125429T1/el unknown
- 2022-05-19 JP JP2022082089A patent/JP7531545B2/ja active Active
- 2022-09-07 AU AU2022228122A patent/AU2022228122B2/en active Active
- 2022-09-09 ZA ZA2022/10065A patent/ZA202210065B/en unknown
- 2022-12-01 US US18/072,959 patent/US20230381276A1/en active Pending
-
2024
- 2024-05-05 IL IL312607A patent/IL312607B2/en unknown
- 2024-07-25 CL CL2024002249A patent/CL2024002249A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3661954T3 (da) | Interleukin-21-muteiner og fremgangsmåder til behandling | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| DK3694529T3 (da) | Trispecifikke proteiner og anvendelsesfremgangsmåder | |
| DK3870579T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3464282T3 (da) | Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse | |
| EP3681479A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| DK3529257T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK4105223T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| IL264949B1 (en) | Therapeutic compression apparatus and methods of use | |
| DK3474996T3 (da) | Tågeapparat og anvendelsesmåde | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3523325T3 (da) | Inducerbare caspaser og fremgangsmåder til anvendelse | |
| DK3551209T3 (da) | Insulin-fc-fusioner og fremgangsmåder til anvendelse | |
| DK3710430T3 (da) | Acss2-inhibitorer og fremgangsmåder til anvendelse deraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3812392T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3727130T3 (da) | Medicinsk system og fremgangsmåde til fremstilling deraf | |
| DK3692009T3 (da) | Biocementationsfremgangsmåde og system | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3720875T3 (da) | Antimikrobielle peptider og fremgangsmåder til anvendelse deraf |